Table 3. ORs (95% CI) for breast cancer by quintiles of serum sex hormone and SHBG levels among postmenopausal women in the NYU Women's Health Study.
|
Quintiles |
||||||
|---|---|---|---|---|---|---|
| Hormone | 1 | 2 | 3 | 4 | 5 | P for trend |
| Oestradiol (pmol l−1) | ||||||
| Cutpoints | <62.87 | 62.87–77.18 | 77.19–92.48 | 92.49–116.34 | >116.34 | |
| #cases/#controls | 47/123 | 61/110 | 52/119 | 62/108 | 72/98 | |
| Model aa | 1.0 | 1.56 (0.95–2.56) | 1.14 (0.69–1.89) | 1.63 (0.98–2.71) | 2.33 (1.40–3.88) | 0.004 |
| Model bb | 1.0 | 1.63 (0.98–2.69) | 1.16 (0.69–1.92) | 1.69 (1.00–2.84) | 2.49 (1.47–4.21) | 0.003 |
| Model cc | 1.0 | 1.52 (0.91–2.53) | 1.08 (0.64–1.80) | 1.50 (0.88–2.55) | 2.06 (1.18–3.60) | 0.04 |
| Oestrone (pmol l−1) | ||||||
| Cutpoints | <74.43 | 74.43–93.02 | 93.03–109.93 | 109.94–133.61 | >133.61 | |
| #cases/#controls | 40/132 | 64/108 | 59/113 | 62/110 | 72/99 | |
| Model aa | 1.0 | 2.26 (1.36–3.78) | 2.12 (1.24–3.62) | 2.35 (1.38–4.02) | 2.97 (1.76–5.02) | <0.001 |
| Model bb | 1.0 | 2.44 (1.43–4.16) | 2.30 (1.32–4.00) | 2.46 (1.41–4.28) | 3.24 (1.87–5.58) | <0.001 |
| Model cc | 1.0 | 2.32 (1.36–3.95) | 2.08 (1.18–3.66) | 2.15 (1.22–3.80) | 2.67 (1.50–4.76) | 0.006 |
| Testosterone (nmol l−1) | ||||||
| Cutpoints | <0.42 | 0.42–0.66 | 0.67–0.94 | 0.95–1.39 | >1.39 | |
| #cases/#controls | 47/125 | 60/112 | 58/114 | 64/108 | 68/103 | |
| Model aa | 1.0 | 1.63 (0.99–2.68) | 1.51 (0.92–2.48) | 1.84 (1.11–3.02) | 2.15 (1.29–3.59) | 0.005 |
| Model bb | 1.0 | 1.69 (1.01–2.81) | 1.57 (0.94–2.61) | 1.93 (1.16–3.23) | 2.37 (1.39–4.04) | 0.002 |
| Model cc | 1.0 | 1.64 (0.98–2.74) | 1.50 (0.90–2.50) | 1.87 (1.12–3.13) | 2.05 (1.19–3.53) | 0.01 |
| Androstenedione (nmol l−1) | ||||||
| Cutpoints | <1.43 | 1.43–2.16 | 2.17–2.90 | 2.91–3.91 | >3.91 | |
| #cases/#controls | 48/123 | 60/112 | 54/117 | 60/111 | 74/97 | |
| Model aa | 1.0 | 1.31 (0.82–2.10) | 1.17 (0.73–1.90) | 1.44 (0.89–2.33) | 2.04 (1.28–3.25) | 0.006 |
| Model bb | 1.0 | 1.29 (0.80–2.10) | 1.20 (0.74–1.97) | 1.45 (0.89–2.37) | 2.07 (1.28–3.33) | <0.001 |
| Model cc | 1.0 | 1.24 (0.77–2.03) | 1.15 (0.70–1.88) | 1.43 (0.87–2.34) | 1.89 (1.16–3.07) | <0.001 |
| DHEAS (μmol l−1) | ||||||
| Cutpoints | <1.15 | 1.15–1.83 | 1.84–2.63 | 2.64–3.97 | >3.97 | |
| #cases/#controls | 50/120 | 56/115 | 56/114 | 64/107 | 69/101 | |
| Model aa | 1.0 | 1.21 (0.76–1.94) | 1.28 (0.79–2.08) | 1.53 (0.95–2.47) | 1.84 (1.12–3.03) | 0.02 |
| Model bb | 1.0 | 1.08 (0.66–1.74) | 1.30 (0.80–2.13) | 1.44 (0.88–2.34) | 1.74 (1.05–2.89) | <0.001 |
| Model cc | 1.0 | 1.08 (0.66–1.75) | 1.23 (0.75–2.01) | 1.39 (0.85–2.27) | 1.61 (0.97–2.69) | <0.001 |
| SHBG (nmol l−1) | ||||||
| Cutpoints | <29.70 | 29.70–40.39 | 40.40–52.31 | 52.32–67.85 | >67.85 | |
| #cases/#controls | 74/98 | 64/108 | 63/109 | 49/123 | 47/125 | |
| Model aa | 1.0 | 0.81 (0.52–1.26) | 0.73 (0.46–1.17) | 0.49 (0.31–0.78) | 0.50 (0.31–0.81) | <0.001 |
| Model bb | 1.0 | 0.77 (0.49–1.22) | 0.73 (0.45–1.17) | 0.46 (0.28–0.75) | 0.51 (0.31–0.82) | <0.001 |
| Model cc | 1.0 | 0.82 (0.51–1.30) | 0.78 (0.48–1.28) | 0.52 (0.31–0.87) | 0.58 (0.34–0.98) | 0.01 |
a
Controlling for matching factors only.
b
Adjusting for age at menarche (continuous), family history of breast cancer (no, one affected first-degree relative >45 years old, one affected first-degree relative <45 years old or more than one affected first-degree relative), parity/age at first birth (nulliparous, ⩽20 years at first full-term pregnancy, 21–25 years at first full-term pregnancy, 26–30 years at first full-term pregnancy, >30 years at first full-term pregnancy), history of total oophorectomy, and history of breast biopsy.
c
Adjusting for all variables in model b, plus body mass index (ln) and height (ln).